News | March 29, 2025
Novo Nordisk strikes $1bn deal for Lexicon’s oral obesity drug
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
Lexicon Pharmaceuticals announces exclusive license agreement with Novo Nordisk for LX9851
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults
The first-of-its-kind study will evaluate potential association between GSK’s shingles vaccine and reduced dementia risk, building on growing body of evidence from observational and retrospective studies
New facility will support plans to advance J&J’s portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases
Adults taking Mounjaro with diet and exercise in a controlled clinical trial lost on average 21.8 kg at the highest dose (15mg) and 15.4 kg at the lowest dose (5mg)
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
The new office in New Delhi marks a significant funding in the APAC region and reinforces the company’s commitment to advancing respiratory care in India
TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
